Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on January 20, 2023. The filing discloses significant changes to the company's executive leadership, specifically the appointment of interim officers to manage operations while a permanent successor is sought.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- Dr. Martin Brenner (Interim CEO): Base salary of $405,000; monthly cash stipend of $7,500 for interim role; target discretionary bonus of 40% of base salary.
- Mr. Felipe Duran (Interim CFO): Base salary increased to $350,000; target discretionary bonus of 40% of base salary; special incentive bonus of $140,000.
- Equity Grants: Dr. Brenner received 130,000 RSUs (fair value ~$91,000) vesting over 12 months, plus a prior grant of 95,348 shares.
Material Changes
The primary material change is the appointment of new interim leadership:
- Interim CEO: Dr. Martin Brenner, previously Chief Scientific Officer, was appointed effective January 20, 2023.
- Interim CFO: Mr. Felipe Duran, previously Vice President of Financial Planning and Analysis, was appointed effective February 13, 2023.
- Search Status: The company is actively searching for a permanent successor to the Chief Executive Officer.
Guidance, Outlook, and Risks
The filing does not contain financial guidance or market outlook. Key operational and contractual details include:
- Employment Terms: Both officers are employed on an "at-will" basis.
- Severance Provisions: Termination without "Cause" triggers 9 months of base salary, pro-rata bonus, and 9 months of health benefits. Termination within 12 months of a Change of Control triggers 12 months of base salary, target bonus, immediate equity vesting, and 12 months of health benefits.
- Retention Conditions: Equity and bonus grants are contingent on continued employment through July 1, 2023, or the achievement of 2023 objectives.
Investor Verification Checklist
- Verify the timeline for the permanent CEO search and any interim operational impacts.
- Review the specific "2023 objectives" defined by the Board that trigger equity vesting and bonus payments.
- Assess the financial impact of the new compensation packages, including the $140,000 special incentive bonus for the CFO and the $91,000 RSU grant for the CEO.
- Confirm the status of the company's cash reserves to support the increased executive compensation and ongoing operations.